Ignite Creation Date:
2025-12-24 @ 10:04 PM
Ignite Modification Date:
2026-01-02 @ 11:36 PM
Study NCT ID:
NCT04191135
Status:
COMPLETED
Last Update Posted:
2025-12-08
First Post:
2019-12-05
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-12-19
Start Date Type:
ACTUAL
Primary Completion Date:
2022-12-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-11-26
Completion Date Type:
ACTUAL
First Submit Date:
2019-12-05
First Submit QC Date:
None
Study First Post Date:
2019-12-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-12-08
Results First Submit QC Date:
None
Results First Post Date:
2024-02-14
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-01
Last Update Post Date:
2025-12-08
Last Update Post Date Type:
ESTIMATED